查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552548

独联体胰岛素市场规模、份额、趋势分析报告：按产品类型、按应用、按分销管道、按地区、按细分市场、预测，2024-2030 年

CIS Insulin Market Size, Share & Trends Analysis Report By Product, By Type (Human Insulin, Insulin Analog), By Application (Type 1 Diabetes), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格
简介目录

独联体胰岛素市场成长与趋势

Grand View Research, Inc.最新报告显示，预计2030年独联体胰岛素市场规模将达到46.7亿美元，2024年至2030年复合年增长率为5.6%。

凭藉广泛的产品组合在未来六年内表现出更高的效力和商业化，该市场预计将成为一个有影响力的渲染驱动力。政府采取旨在透过降价提高胰岛素负担能力的倡议，可以对需求产生积极影响，正如 2013 年乌克兰政府和 Indar 合作将胰岛素价格降低 20% 预计会产生影响一样。该市场的其他驱动因素包括製造商越来越多地利用开拓的机会，开设新的生产设施来改善胰岛素的供应，以及二型糖尿病患病率的增加，这预计将成为推动未来市场成长的一个因素。

CIS 胰岛素市场报告亮点

  • 由于市场驱动因素、限制因素、机会因素和威胁因素等影响市场成长的各种因素，波兰独联体胰岛素市场在 2023 年获得了 10.3% 的显着市场占有率。
  • 长效胰岛素占市场主导地位，2023年占52.7%的份额。长效胰岛素模仿天然胰岛素，起效较慢，主要作为基础胰岛素。
  • 1 型糖尿病占据市场主导地位，2023 年占 79.6% 的份额。 1 型糖尿病主要影响儿童、青少年和一些成年人。由于独联体地区盛行率不断上升，预计 2 型糖尿病在预测期内的复合年增长率将达到 11.6%。
  • 2023 年，胰岛素类似物以 89.0% 的最大销售份额引领市场。胰岛素类似物是一种人工胰岛素，可以快速起效并对身体功能产生即时的效果。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章 CIS 胰岛素市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • CIS 胰岛素市场分析工具
    • 波特的分析
    • PESTEL分析

第 4 章 CIS 胰岛素市场：按产品分类的估计和趋势分析

  • 细分仪表板
  • 独联体胰岛素市场：产品变化分析，百万美元，2023 年和 2030 年
  • 速效胰岛素
  • 长效胰岛素
  • 复合胰岛素
  • 生物相似药
  • 其他的

第五章 独联体胰岛素市场：按类型估计和趋势分析

  • 细分仪表板
  • 独联体胰岛素市场：类型变异分析，百万美元，2023 年和 2030 年
  • 人类胰岛素
  • 胰岛素类似物

第六章 CIS 胰岛素市场：按应用、估计和趋势分析

  • 细分仪表板
  • 独联体胰岛素市场：应用变化分析，百万美元，2023 年和 2030 年
  • 1型糖尿病
  • 2型糖尿病

第 7 章 独联体胰岛素市场：按分销管道的估计和趋势分析

  • 细分仪表板
  • 独联体胰岛素市场：分销管道变化分析，百万美元，2023 年和 2030 年
  • 医院药房
  • 零售/专业药房
  • 其他的

第 8 章 独联体胰岛素市场：区域、估计与趋势分析

  • 2023 年及 2030 年独联体胰岛素市场占有率（按地区），百万美元
  • 独立国协(CIS)
    • 俄罗斯
    • 波兰
    • 土耳其
    • 乌克兰
    • 乌兹别克
    • 白俄罗斯
    • 哈萨克
    • 其他独联体国家

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Eli Lilly and Company
    • Sanofi SA
    • Boehringer Ingelheim International GmbH
    • Oramed Pharmaceuticals Inc.
    • Novo Nordisk A/S
    • Merck &Co., Inc.
    • Bristol-Myers Squibb Company
    • Novartis AG
简介目录
Product Code: 978-1-68038-170-2

CIS Insulin Market Growth & Trends:

The CIS insulin market size is expected to reach USD 4.67 billion by 2030, registering a CAGR of 5.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The presence of an extensive pipeline portfolio of products exhibiting higher efficacies and their subsequent commercialization over the next six years is expected to serve this market as a high impact rendering driver. The introduction of government initiatives aimed at improving the affordability of insulin via price reduction, such as the collaboration between the government of Ukraine and Indar to reduce the price of insulin by 20% in 2013 is expected to have positive influence on demand. Some of the other drivers of this market include increasing attempts made by manufacturers to capitalize on the untapped opportunities by opening new manufacturing units to improve the supply of insulin and growing incidence rates of type II diabetes are some of the factors expected to fuel future market growth.

CIS Insulin Market Report Highlights:

  • Poland CIS Insulin market held a substantial market share of 10.3% in 2023 due to various factors influencing market growth, including drivers, constraints, opportunities, and threats
  • Long-acting Insulin dominated the market and accounted for a share of 52.7% in 2023. Long-acting insulins mimic natural insulin with a slower onset of action and are mainly utilized as basal insulins.
  • Type 1 Diabetes dominated the market and accounted for a share of 79.6% in 2023. Type 1 diabetes primarily affects children, teenagers, and some adults. Type 2 Diabetes is expected to register the fastest CAGR of 11.6% during the forecast period, driven by the increasing prevalence of the condition in the CIS region.
  • Insulin analog led the market with the largest revenue share of 89.0% in 2023. Insulin analogs are a form of engineered insulin that starts working quickly and has an instant impact on the body's functions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. CIS Insulin Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. CIS Insulin Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. CIS Insulin Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. CIS Insulin Market: Product Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Rapid-acting Insulin
    • 4.3.1. Rapid-acting Insulin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Long-acting Insulin
    • 4.4.1. Long-acting Insulin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Combination Insulin
    • 4.5.1. Combination Insulin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Biosimilar
    • 4.6.1. Biosimilar Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Other Products
    • 4.7.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. CIS Insulin Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. CIS Insulin Market: Type Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Human Insulin
    • 5.3.1. Human Insulin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Insulin Analog
    • 5.4.1. Insulin Analog Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. CIS Insulin Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. CIS Insulin Market: Application Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Type I Diabetes
    • 6.3.1. Type I Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Type II Diabetes
    • 6.4.1. Type II Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. CIS Insulin Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. CIS Insulin Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
  • 7.3. Hospital Pharmacies
    • 7.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Retail & Specialty Pharmacies
    • 7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Other Distribution Channels
    • 7.5.1. Other Distribution Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. CIS Insulin Market: Regional Estimates & Trend Analysis

  • 8.1. CIS Insulin Market Share, By Region, 2023 & 2030, USD Million
  • 8.2. Commonwealth of Independent States (CIS)
    • 8.2.1. CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. Russia
      • 8.2.2.1. Russia CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Poland
      • 8.2.3.1. Poland CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Turkey
      • 8.2.4.1. Turkey CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.5. Ukraine
      • 8.2.5.1. Ukraine CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.6. Uzbekistan
      • 8.2.6.1. Uzbekistan CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.7. Belarus
      • 8.2.7.1. Belarus CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.8. Kazakhstan
      • 8.2.8.1. Kazakhstan CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.9. Rest of CIS
      • 8.2.9.1. Rest of CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. Eli Lilly and Company
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/Strategic Initiatives
    • 9.4.2. Sanofi S.A.
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/Strategic Initiatives
    • 9.4.3. Boehringer Ingelheim International GmbH
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/Strategic Initiatives
    • 9.4.4. Oramed Pharmaceuticals Inc.
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/Strategic Initiatives
    • 9.4.5. Novo Nordisk A/S
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/Strategic Initiatives
    • 9.4.6. Merck & Co., Inc.
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/Strategic Initiatives
    • 9.4.7. Bristol-Myers Squibb Company
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/Strategic Initiatives
    • 9.4.8. Novartis AG
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/Strategic Initiatives